Evidence map›Paper›PMID 40836575›Full record

ArticleFuture medicinal chemistry2025

Novel strategies for inhibiting SufA protease: the role of ester substituents and biological properties.

Ewa Burchacka, Paweł Pięta, Katarzyna Pstrowska, Agnieszka Korzenowska-Kowal, Gabriela Cieniuch, Michał Jewgiński

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ewa BurchackaDepartment of Organic and Medicinal Chemistry, Faculty of Chemistry, Wrocław University of Science and Technology, Wrocław, Poland.ORCID 0000-0003-2177-1800
Paweł PiętaDepartment of Cell Biology, Poznan University of Medical Sciences, Poznań, Poland.
Katarzyna PstrowskaDepartment of Advanced Material Technologies, Faculty of Chemistry, Wrocław University of Science and Technology, Wrocław, Poland.
Agnieszka Korzenowska-KowalCollection of Microorganisms, Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Gabriela CieniuchCollection of Microorganisms, Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Michał JewgińskiDepartment of Bioorganic Chemistry, Faculty of Chemistry, University of Science and Technology, Wrocław, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study aims to develop novel antibacterial agents by targeting SufA protease, a key virulence factor in Finegoldia magna, using 1-aminoalkylphosphonate (1-AAP) diaryl esters as inhibitors. MATERIALS &

methodsStructural optimization of a reference inhibitor, Cbz-6-AmNpthP(OC₆H₅)₂, was performed by introducing substituents at the para position of phenyl rings: -SCH₃ (

resultsCompound

conclusions1-AAP derivatives, particularly 8a and 8c, exhibit promising antibacterial properties. These findings validate SufA as a therapeutic target and support further development of peptide-based inhibitors to enhance efficacy and selectivity.

Indexed as

Anti-Bacterial AgentsEstersProtease InhibitorsMicrobial Sensitivity TestsModels, MolecularMolecular Docking SimulationOrganophosphonatesStructure-Activity RelationshipAnti-Bacterial AgentsEstersOrganophosphonatesProtease Inhibitorsantibacterial treatmentinhibitorsphosphonateSerine proteasesSufA protease

Identifiers

PMID40836575
PMCPMC12380226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.